

nomegestrol or one of its esters sufficient to prevent osteoporosis and cardiovascular disorders.

20. The method of claim 19 in which the estradiol derivative is 17 β -estradiol.

21. The method of claim 19 in which the estradiol derivative is estradiol valerate.

22. The method of claim 19, in which the estradiol derivative equine estrogen is present in an amount ranging from 0.3 to 3 mg per unitary dose.

23. The method of claim 19, in which the estradiol derivative is conjugated equine estrogens.

24. The method of claim 19, in which the estradiol derivative is present in an amount of 0.3 to 3 mg per unitary dose.

25. The method of claim 19 in which the estradiol is present in the free form in an amount of 0.5 to 1.5 mg per unitary dose.

26. The method of claim 19 in which estradiol valerate is present in an amount of 1.5 to 2 mg per unitary dose.

27. The method of claim 18, in which conjugated equine estrogen is present in an amount of 0.312 to 0.625 mg per unitary dose.

28. The method of claim 19 in which the progestative is nomegestrol acetate.

29. The method of claim 19, in which the nomegestrol acetate is present in an amount of 0.3 to 1.5 mg per unitary dose.

30. The method of claim 19, in which the nomegestrol acetate is present in an amount of 0.625 to 1.25 mg per unitary dose.

SPK
aa2
Cancel claims 1, 2, 10 and 14 to 17.

Claim 3 (amended) The method of claim 18, in which the estradiol derivative is 17 β -estradiol.

Claim 4 (amended) The method of claim 18, in which the estradiol derivative is estradiol valerate.

Claim 5 (amended) The method of claim 18, in which the estradiol derivative is conjugated equine estrogens.

Claim 6 (amended) The method of claim 18, in which the estradiol derivative is present in an amount of 0.3 to 3 mg per unitary dose.

Claim 7 (amended) The method of claim 18 in which estradiol is present in the free form in an amount of 0.5 to 1.5 mg per unitary dose.

Claim 8 (amended) The method of claim 14, in which estradiol valerate is present in amount of 1.5 to 2 mg per unitary dose.

Claim 9 (amended) The method of claim 5, in which conjugated equine estrogen is present in an amount of 0.312 to 0.625 mg per unitary dose.

aa3
Claim 11 (amended) The method of claim 18, in which the progestative is norgestrol acetate.

Claim 12 (amended) The method of claim 11, in which the norgestrol acetate is present in an amount of 0.3 to 1.5 mg per unitary dose.

Claim 13 (amended) The method composition of claim 11, in which the norgestrol acetate is present in an amount of 0.625 to 1.25 mg per unitary dose.